The web of causation is closing in on EB virus in its relation to certain conditions. In heterophile positive infectious mononucleosis the web of causation seems established beyond any reasonable doubt (1-3). The evidence derived from prospective serological studies that EBV antibody is regularly absent prior to infectious mononucleosis and regularly appears during illness (4-7) is supported by the demonstration of EBV-specific IgM antibody indicative of a primary infection (8-10), by identification of the virus in lymphocytes cultured from the blood (1) by isolation of the virus from the throat ( 1 1-13 ), and by suggestive experimental evidence of infectious mononucleosis in squirrel monkeys (14) and gibbons (15) inoculated with EBV or EBV-infected cells. The immunological events that turn infectious mononucleosis on and turn it off are not so clear, although evidence is rapidly accumu--lating on these questions. Figure 1 presents a working schema of pathogenesis. EB virus appears to enter the oropharynx in young adults, probably thru kissing, and multiplies locally producing a lytic and persistent infection (16). It enters the blood stream and possibly the gut although the latter has not yet been established. Lymphocytes of the B-type are infected and a nonproductive infection of long duration is established. Some of these transformed B cells may contribute early to the atypical lymphocytosis. Current evidence then suggests that there is mixed lymphocyte reponse of T cells to B cells altered by an EBV-membrane induced antigen. This results in T cell proliferation (17), transformation, and a major outpouring of atypical lymphocytes. Lymphocytes from acute cases of infectious mononucleosis have also been found to cause stimulation of convalescent leukocytes from the same 'From the WHO Serum Reference Bank.
The web of causation is closing in on EB virus in its relation to certain conditions. In heterophile positive infectious mononucleosis the web of causation seems established beyond any reasonable doubt (1) (2) (3) . The evidence derived from prospective serological studies that EBV antibody is regularly absent prior to infectious mononucleosis and regularly appears during illness (4-7) is supported by the demonstration of EBV-specific IgM antibody indicative of a primary infection (8) (9) (10) , by identification of the virus in lymphocytes cultured from the blood (1) by isolation of the virus from the throat ( 1 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] , and by suggestive experimental evidence of infectious mononucleosis in squirrel monkeys (14) and gibbons (15) inoculated with EBV or EBV-infected cells. The immunological events that turn infectious mononucleosis on and turn it off are not so clear, although evidence is rapidly accumu--lating on these questions. Figure 1 presents a working schema of pathogenesis. EB virus appears to enter the oropharynx in young adults, probably thru kissing, and multiplies locally producing a lytic and persistent infection (16) . It enters the blood stream and possibly the gut although the latter has not yet been established. Lymphocytes of the B-type are infected and a nonproductive infection of long duration is established. Some of these transformed B cells may contribute early to the atypical lymphocytosis. Current evidence then suggests that there is mixed lymphocyte reponse of T cells to B cells altered by an EBV-membrane induced antigen. This results in T cell proliferation (17) , transformation, and a major outpouring of atypical lymphocytes. Lymphocytes from acute cases of infectious mononucleosis have also been found to cause stimulation of convalescent leukocytes from the same HYPOTHETICAL (16) . The mechanism of heterophile production is still unexplained but the knowledge that its appearance is most common in EBV infections of young adults (2) (26, 27) and/or of EB nuclear antigen (23) from a total of about 120 cases; (5) the experimental production of reticulum cell sarcomas in cotton-top marmosets using EBV-infected marmoset cells or cell-free EBV by Shope et al. (28) with the ability to recover EBV from these tumor cells; and similar results in owl monkeys (29) ; (6) (23) (24) (25) (26) (27) and antibody has been absent in the sera of 2 cases. Furthermore, in American patients diagnosed histologically as Burkitt lymphoma EBV antibody has been absent from the serum of 19% of the cases in 2 separate studies (31) (32) , present but without elevation in titer in many others (31) (32) (33) , and without demonstrable EBV genome in the biopsy tissues of 4 American Burkitt lymphoma cases (34) . In addition to EB virus as a causative agent, there is strong epidemiologic evidence incriminating malaria as an important cofactor in African Burkitt lymphoma to account for the high incidence of Burkitt lymphomas in Africa and New Guinea (35, 36) . The mechanism for this enhanced susceptibility is not clear but might be due to antigen-antibody malarial complexes (blocking factors) interfering with cell-mediated (T lymphocyte) responses to EBV infection resulting in viral persistence and tumor formation. The study of cell-mediated immunity in Burkitt lymphoma is just beginning. Fass et al. (37) have shown delayed hypersensitivity reactions in Burkitt lymphoma patients exposed to autologous tumor cell extracts, but it is not known whether these reactions are directed against EBV-induced antigens or not. The positive reactions correlated with sustained remissions.
The web of causation for EBV in nasopharyngeal carcinoma is of the same general order as in African Burkitt lymphoma: EBV antibody is almost universally present in the serum, the antibody titer is very high in 80% of the cases and the EBV genome has been demonstrated not only in the lymphocyte infiltrated tumor (26) but in the epithelial cells themselves (38) . A lead as to how EB virus produces infection in epithelial cell in vivo when it is usually limited to lymphocytes in vitro has been provided by the demonstration that hybrid cells consisting of an epithelial line and BL lymphocytes fused with Sendai virus, and stimulated by BUDR, support the persistence of EBV genome (39) . The possible existence of an in vivo fusion factor has been suggested by the occurrence of elevated antibody titers to herpes simplex type 1 (40a) and to parainfluenza type 3 viruses (40b) in sera from cases of nasopharyngeal cancer.
EB virus and a cofactor virus producing fusion are 2 potential ingredients in the causation of nasopharyngeal cancer. A third important ingredient is genetic susceptibility. It was early recognized that persons of Chinese descent, especially from southern China, were at 10-50 times the risk of developing nasopharyngeal cancer than caucasians in the same environment (41, 42 (50, 61, 62) and in systemic lupus erythematosus (63) , and that a serum inhibitor of cell-mediated immunity may be present in sarcoidosis (64) . The (52) and in immune complex nephritis (66) . Low or absent circulating antibody has also been observed in mice in lymphocytic choriomeningitis, in murine leukemia, and in lactic acid dehydrogenase-virus immune complex glomerulonephritis (67) (68) (69) (70) .
A selected impairment in cell-mediated immunity has been proposed as a common denominator in EBV-associated infections (71, 72) resulting in virus persistence or reactivation. The mechanism by which this might occur is not entirely clear but increasing attention is being directed to the T lymphocyte in its role in the recognition and control of viral infections and of their reactivation. The T lymphocytes may be deficient in numbers, tied up in other tasks (antigenic competition), genetically lack appropriate receptors for EBV or EBV-induced antigens, be blocked in their task by serum inhibitors, or rendered ineffective by immuno-suppressant drugs. Suppressor T cells may block the action of other T cells. Intensive study of cell-mediated immunity in EBV infections is in order with special focus on whether T cells respond normally to EB virus in infectious mononucleosis, Burkitt lymphoma and nasopharyngeal cancer as well as in other EBV-associated conditions. A method for such stimulation has been published by Gerber and Lucas (73) . It has been recently shown that patients who are immunosuppressed during renal transplantation or for therapeutic reasons excrete EB virus from the pharynx more commonly than controls, and that the infection may be reactivated (74) . There is clearly an increased risk for certain types of cancer in persons given immunosuppressant drugs in high dosage (75) . This is of the order of 35 times higher than normal, particularly for reticulum-cell sarcoma.
The presence of high antibody levels to certain viruses thus appears to be associated with an increased risk to some malignancies, to chronic diseases like SLE and sarcoidosis, as well as to chronic neurologic diseases like progressive multifocal leukoencephalopathy (papovavirus), subacute sclerosing panencephalitis and multiple sclerosis (both associated with measles virus). The critical evidence lacking is whether these high titers precede the disease and thus play a causal role, accompany the disease expressing a common immunologic defect with the real cause of the disease, or follow in the wake of the disease as a consequence of depressed cell-mediated immunity induced by the disease itself. This temporal sequence may vary in different diseases. The retrospective approach also fails to identify other possible diseases associated with high antibody titers and does not permit assessment of risk factors. It is important now to mount large scale prospective seroepidemiologic studies which would (1) identify healthy individuals who have high antibody titers to EBV, rubella, parainfluenza, measles, papavo virus, herpes type 2 viruses etc. and/or have impaired lymphocyte responses to these viruses;5 (2) seek evidence of viral excretion and persistence; (3) follow such persons and matched controls, who have normal antibody levels, for the occurrence of cancer, chronic diseases, and neurological disorders, especially those of unknown cause associated with defects in cell-mediated immunity,; or in which immunc complexes are suspected as playing a role in the pathogenesis; (4) carry out intensive virological and immunological studies when a chronic disease occurs, including a search for the virus or viral genome in affected tissues. The results should be compared with matched controls, whenever possible. If one takes the total incidence of all of the malignant and chronic diseases in which viruses may play a role, then the return from such a costly venture should make it justifiable and make the population base manageable. The populations served by large health plans caring for all ages would be an admirable start because of their accessibility to bleeding on entry into the plan and at periodic intervals thereafter and because of the possibility of good clinical surveillance. Indeed, it might not be necessary to carry out viral antibody tests until a disease develops provided frozen serum and lymphocyte samples were available prior to this time from the patient and from suitable controls.
From the epidemiologist's standpoint there are factors that might obscure a true causal relationship between EB virus and the chronic conditions with which it is 'Prospective analysis of cancer and chronic diseases according to their HLA type should also be included, if possible.
'The major ones of current interest are lymphomas, leukemia, cervical and penile cancer, SLE, rheumatoid arthritis, sarcoidosis, immune complex, kidney disease, chronic neurological diseases. associated. EBV (76) . Full acceptance will require much more evidence to satisfy everyone. Virologically, this includes further attempts to produce lymphomas in primates using purified EBV derived from a Burkitt lymphoma and in the presence or absence of concomitant experimental malaria; assessment of the role, if any, of an RNA virus in this setting, and expanded efforts to identify the EBV genome and/or nuclear antigen in various tissues from patients with lymphoma, NPC, other cancers, and controls. Epidemiologically, prospective surveys must establish that EBV infection and high antibody titers precede the disease and that such high titers are associated with a higher risk of tumor than in those with normal antibody titers; control of a cofactor such as malaria in Burkitt lymphoma or a myxovirus infection in NPC should decrease the incidence of the associated tumor. Genetically, the relation of HLA and similar antigens to NPC must be clarified and the role of these genetic attributes explored in other conditions associated with high EBV antibody levels.
Immunologically, the mechanism of viral persistence and/or reactivation in these conditions need further analysis, particularly the specific responses of lymphocytes to EBV, myxoviruses, and malaria. Therapeutically, the possible effect of transfer factor derived from lymphocytes of EBV-immune subjects should be cautiously explored in controlled trials of Virusforsch. 37, 332-339 (1972) .
